Marshall Wace

Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Founded in 2000, Sammaan Capital is an Indian non-banking financial company specializing in mortgage lending. It offers home loans, loans for NRIs, and loans against properties at competitive interest rates to salaried individuals and self-employed professionals within a relatively short processing time.

Aviceda Therapeutics is a late-stage biotechnology company developing immunomodulators using glycobiology to target innate immune cells and treat chronic inflammation. Its cell-based high-throughput screening platform enables rapid discovery of ligands for various immune cells, with applications in eye diseases, fibrosis, neurology, and oncology.

35Pharma is a biopharmaceutical company that designs and develops innovative biologics to address diseases with high unmet medical need. The company applies protein engineering and a deep understanding of transforming growth factor-beta structure-function relationships to create potent ligand traps for cardio-pulmonary and metabolic diseases, including pulmonary hypertension and musculoskeletal disorders.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Inquis Medical is a company focused on developing innovative thrombectomy technology aimed at enhancing the management of venous thromboembolic diseases. The company’s medical devices are designed to address unmet clinical needs and improve the standard of care in this field. By offering an efficient single-pass thrombectomy solution with minimal blood loss, Inquis Medical aims to provide healthcare professionals with advanced tools that can significantly impact patient outcomes and long-term health management.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

Pathalys Pharma is a biopharmaceutical company dedicated to developing therapeutics for late-stage chronic kidney diseases. Its primary focus is improving treatment for secondary hyperparathyroidism, an unmet need in healthcare.

Human Interest is a retirement savings provider focused on small and medium-sized businesses, offering a 401(k) platform that simplifies administration and compliance through end-to-end technology. The platform automatically creates employee accounts, syncs payroll deductions, and provides personalized investment guidance, enabling SMBs to offer affordable, easy-to-manage retirement plans; the company has served thousands of businesses across the United States and was founded in 2015 in San Francisco by Paul Sawaya and Roger Lee.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Mind Medicine Inc. is a biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies aimed at addressing addiction and mental health issues. Headquartered in New York, the company is building a diverse drug development pipeline that includes innovative treatments derived from psychedelic substances such as Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative known as 18-MC. Founded in 2010 by JR Rahn, Scott Freeman, Leonard Latchman, and Stephen L. Hurst, MindMed is actively engaged in forming collaborations and conducting clinical trials to further explore the therapeutic potential of these substances in treating brain health disorders.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

BlueWhale Bio is a biotechnology company spun out from the University of Pennsylvania. It focuses on accelerating the use of cell-based therapies by innovating in manufacturing processes.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

InspireMD, Inc. is a medical device company based in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology aimed at treating vascular and coronary diseases. The company offers two primary products: the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, used in patients with acute coronary syndromes and saphenous vein graft interventions. InspireMD is also working on the NGuard neurovascular flow diverter, which aims to divert blood flow from cerebral aneurysms to enhance patient outcomes. The company's products are marketed through local distributors in various regions, including Europe, Latin America, the Middle East, and Asia.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Thunes is a global B2B payment infrastructure platform established in 2016, specializing in cross-border payment solutions. It facilitates seamless fund transfers between various payment systems, catering to a diverse range of clients, including major players in the gig economy and fintech sectors. The platform enables businesses and consumers to send and receive payments in 80 currencies across 132 countries, supporting 300 payment methods. Thunes offers a suite of services including remittance processing, mass payouts, virtual accounts, and payment collection, utilizing application programming interfaces (APIs) to enhance accessibility and reduce transaction costs. In April 2022, the company expanded its capabilities by acquiring a controlling stake in Tookitaki, a compliance platform that strengthens its anti-money laundering and fraud prevention measures. Headquartered in Singapore, Thunes operates regional offices in key global cities such as London, Paris, and Dubai, positioning itself as a vital player in the international payment landscape.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.

TRM Labs Inc. is a blockchain intelligence company that provides a platform focused on token relationship management, utilizing machine learning to assist clients in managing customer relationships and detecting suspicious activities. The platform offers solutions for on-chain anti-money laundering (AML) compliance, including customer due diligence, transaction monitoring, and relationship management specifically tailored for digital asset firms. Additionally, TRM Labs develops enterprise applications and tools that enable organizations to launch blockchain-based products aimed at identifying fraudulent activities such as money laundering and market manipulation. Founded in 2017 and headquartered in San Francisco, California, the company serves a diverse clientele, including financial institutions, cryptocurrency businesses, and government agencies, and has established partnerships with notable organizations such as PayPal, Visa, and federal agencies. TRM Labs is committed to enhancing the safety of the financial ecosystem through advanced data engineering and threat intelligence, backed by a team of experts with extensive experience in law enforcement and technology.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Neurolens is a company founded in 2012 and based in Costa Mesa, California, specializing in innovative vision solutions. It develops prescription lenses that incorporate a contoured prism to enhance eye alignment, addressing common issues such as headaches, neck or shoulder pain, and eyestrain that often arise from prolonged use of digital devices, reading, or detailed tasks. Neurolens also offers a vision measurement device system that utilizes an advanced eye-tracking technology to detect even minor misalignments in the eyes. This capability enables effective treatment for patients suffering from chronic headaches and other related symptoms, making Neurolens a key player in the vision correction market.

21Shares is a provider of crypto exchange-traded products and indices that track baskets of top cryptocurrencies. It develops listed products such as diversified crypto baskets and uses the Onyx issuance platform to issue and manage crypto ETPs worldwide. The company's mission is to offer investors easy, regulated access to crypto through existing bank and brokerage accounts. Founded in 2018 and based in Zug, Switzerland, with offices in Zurich, New York, and Berlin, it rebranded from Amun and has supported the first cryptocurrency index listing on SIX Swiss Exchange.

21.co is a cryptocurrency company providing access to crypto through simple and easy-to-use products. 21.co is the parent company of 21Shares, the world’s largest issuer of cryptocurrency exchange-traded products (ETPs) – which is powered by Onyx, a proprietary technology platform used to issue and operate cryptocurrency ETPs for 21Shares and third parties – in addition to Amun, a token provider focused on making the Defi world more accessible. The company was founded in 2018 by Hany Rashwan and Ophelia Snyder. 21.co is registered in Zug, Switzerland with offices in Zurich and New York.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

Turtlemint is an online insurance platform based in Mumbai, Maharashtra, India, that simplifies the process of buying and managing insurance policies. Founded in 2015, the company aims to make insurance accessible and understandable by demystifying complex jargon and providing user-friendly tools. Turtlemint offers a range of insurance products, including car, bike, health, and term life insurance, allowing customers to search, compare, and purchase policies entirely online with just a few clicks. The platform leverages proprietary algorithms and data analytics to provide personalized recommendations, while also offering a network of offline facilitators to assist with the purchase and claims process. This comprehensive approach enables clients to select the right insurance schemes tailored to their needs.

Circle is a Boston-based fintech company founded in 2013 by Jeremy Allaire and Sean Neville. It specializes in utilizing stablecoins for payments, e-commerce, and investment products. Circle's services include Circle Pay for easy money transfers, Circle Invest for crypto asset trading, and Circle Trade for over-the-counter transactions. The company is backed by prominent investors such as Jim Breyer, Goldman Sachs, IDG Capital, General Catalyst, and Accel Partners.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Lukka, Inc. is a blockchain-native technology company based in New York that specializes in providing middle and back office solutions for the crypto-asset ecosystem. Founded in 2014 and rebranded from Libra Services, Inc. in 2019, Lukka focuses on managing and processing complex blockchain and cryptocurrency data to enhance accessibility and utility for businesses. Its offerings include LukkaTax, which simplifies tax calculations and compliance for cryptocurrency transactions, and LukkaCrypto Office, a back-office solution for managing crypto assets that features pricing, valuation, and reporting capabilities. Additionally, Lukka Reference Data ensures the consistency and accuracy of crypto asset data for enterprise applications. By automating and optimizing accounting, audit, and tax processes, Lukka delivers real-time visibility into crypto transaction activity, catering to the reporting and compliance needs of funds, fund administrators, exchanges, and enterprises.

Accelerant is a data-driven insurtech and specialty insurance marketplace that operates as a wholesale risk exchange, connecting selected specialty underwriters with risk capital partners to provide capacity for insured pools. The platform leverages granular policy data and analytics to deliver risk insights, support long-term capacity commitments, and maintain a diversified portfolio with low catastrophe and systemic risk. Based in London, Accelerant serves North America and the UK/EU, with emphasis on the UK and EU markets for revenue. It was founded in 2018 and has earned an AM Best rating of A- (Excellent).

Tipalti, Inc., established in 2010, specializes in accounts payable automation and global mass payments. Headquartered in San Mateo, California, with an additional office in Israel, the company offers a comprehensive software solution that streamlines and automates the process of paying suppliers, partners, and publishers worldwide. Tipalti's platform covers all aspects of the payables workflow, including supplier onboarding, invoice processing, global funds disbursement, tax compliance, and payment reconciliation. By utilizing Tipalti, businesses can significantly reduce their supplier payment workload, strengthen financial controls, ensure regulatory compliance, and improve partner payment experiences, enabling them to focus on strategic growth.

TRM Labs Inc. is a blockchain intelligence company that provides a platform focused on token relationship management, utilizing machine learning to assist clients in managing customer relationships and detecting suspicious activities. The platform offers solutions for on-chain anti-money laundering (AML) compliance, including customer due diligence, transaction monitoring, and relationship management specifically tailored for digital asset firms. Additionally, TRM Labs develops enterprise applications and tools that enable organizations to launch blockchain-based products aimed at identifying fraudulent activities such as money laundering and market manipulation. Founded in 2017 and headquartered in San Francisco, California, the company serves a diverse clientele, including financial institutions, cryptocurrency businesses, and government agencies, and has established partnerships with notable organizations such as PayPal, Visa, and federal agencies. TRM Labs is committed to enhancing the safety of the financial ecosystem through advanced data engineering and threat intelligence, backed by a team of experts with extensive experience in law enforcement and technology.

ConsenSys is an Ethereum software and Web3 company that enables developers, enterprises, and individuals to build decentralized applications, deploy modern financial infrastructure, and access the decentralized web. Its product suite includes Infura, Quorum, Truffle, Codefi, MetaMask, and Diligence, serving millions of users and supporting billions of blockchain-based queries and digital assets. Built on Ethereum, ConsenSys fosters the growth of a programmable economy by providing tools, services, and research that accelerate innovation and the mainstream adoption of blockchain technology.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Vayana Network facilitates electronic capture of trade receivables and payables, enabling businesses to finance these through banks and financial institutions. It offers solutions for payable financing, receivable factoring, and supply chain financing.

CRED is a members-only application that incentivizes users by offering exclusive rewards for timely credit card bill payments. The platform promotes financial responsibility by encouraging users to maintain good credit scores while rewarding them with various offers and discounts on shopping, health services, and other expenditures. CRED prioritizes the protection of user data through stringent security processes and compliance with regulatory standards, ensuring transparency and opt-in consent for data usage. By facilitating on-time credit card payments, CRED not only helps users manage their finances better but also enhances their overall spending experience with valuable rewards.

Varo Money, Inc. is a digital bank based in San Francisco, California, that offers a range of online banking products and services, including bank and savings accounts, checking accounts, and overdraft protection. Established in 2015 and known for being the only U.S. consumer fintech with a national bank charter, Varo aims to serve as a comprehensive banking partner for millions of Americans, especially those seeking better financial solutions. The company combines fintech innovation with the security of a chartered bank, providing tools and insights to enhance financial resilience for its customers. Varo's platform also includes features such as spending analysis, real-time budgeting, cash flow forecasts, direct deposits, and online bill payments, all designed to empower users to make informed financial decisions and improve their overall financial well-being.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company based in Campbell, California, focused on developing innovative therapies for gastrointestinal disorders. Incorporated in 2017, the company specializes in creating products that address unmet medical needs related to the enteric nervous system. One of its lead products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx aims to provide effective solutions for functional and motility gastrointestinal disorders, targeting issues related to gut contractions, sensation, and the brain-gut axis, thereby addressing significant patient needs and alleviating disease burdens.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Circle is a Boston-based fintech company founded in 2013 by Jeremy Allaire and Sean Neville. It specializes in utilizing stablecoins for payments, e-commerce, and investment products. Circle's services include Circle Pay for easy money transfers, Circle Invest for crypto asset trading, and Circle Trade for over-the-counter transactions. The company is backed by prominent investors such as Jim Breyer, Goldman Sachs, IDG Capital, General Catalyst, and Accel Partners.

Pine Labs provides a merchant platform offering technology and financial solutions to help businesses increase revenue and reduce costs. It connects financial institutions and consumer brands, enabling merchants to deliver value to customers through offline and online transactions. The company's cloud-based platform powers over 350,000 POS terminals across India and Malaysia, serving more than 100,000 merchants across various sectors.

Forge Biologics, Inc. is a contract development and manufacturing organization (CDMO) specializing in gene therapies and genetic medicines. Founded in 2019 and based in Columbus, Ohio, the company focuses on developing and manufacturing therapeutics, particularly for viral vector gene therapies aimed at treating genetic diseases. Notably, it offers a novel approach combining adeno-associated virus (AAV) and umbilical cord transplant to address infantile Krabbe disease, a severe neurodegenerative disorder. Additionally, Forge Biologics collaborates with scientists, physicians, biotech and pharmaceutical companies, and patient groups to facilitate the progression of gene therapy programs from preclinical development through to clinical and commercial-scale manufacturing. The company is committed to enabling access to transformative medicines for patients suffering from rare genetic diseases.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Flywire facilitates global payments for educational institutions and their students worldwide. It offers a secure platform supporting diverse payment methods in over 140 currencies across 240 countries.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

International Airlines Group (IAG) is one of the largest airline groups globally, primarily engaged in the transportation of passengers and cargo. It operates multiple well-known subsidiaries, including British Airways, Iberia, Vueling, and Aer Lingus, which maintain their distinct brands while benefiting from the group's combined resources. IAG's main airport hubs are located in London, Madrid, Barcelona, and Dublin, allowing it to enhance its global presence. The group's revenue is predominantly generated from the United Kingdom, with significant contributions also from Spain, the United States, and other international markets. Each airline within the group is managed as a separate operating company, facilitating tailored strategies and resource allocation.

Founded in 2003, LGI Homes specializes in designing, constructing, and selling new homes across the United States. Its product offerings include entry-level detached and attached homes, move-up homes under the LGI Homes brand, and luxury series homes under Terrata Homes. With operations in over a dozen states, LGI Homes focuses on providing quality housing options to diverse markets.